Measurable residual disease testing in acute myeloid leukaemia

• Published in: Leukemia Vol. 31; no. 7; pp. 1482 - 1490
• Main Authors: Hourigan, C S, Gale, R P, Gormley, N J, Ossenkoppele, G J, Walter, R B
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2017; Nature Publishing Group
• Subjects: 692/308/2779/109; 692/699/1541/1990/283/1897; Abnormalities; Acute myelocytic leukemia; Acute myeloid leukemia; Assaying; Cancer Research; Care and treatment; Clinical trials; Critical Care Medicine; Cytogenetics; Decision Making; Drug and Narcotic Control; Drug Discovery; Hematology; Humans; Intensive; Internal Medicine; Intervention; Leukemia; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - drug therapy; Medical tests; Medicine; Medicine & Public Health; Minimal residual disease; Neoplasm, Residual - diagnosis; Oncology; Phenotypes; Predictions; Recurrence; Remission; review; Risk; Standardization; Therapy

There is considerable interest in developing techniques to detect and/or quantify remaining leukaemia cells termed measurable or, less precisely, minimal residual disease (MRD) in persons with acute myeloid leukaemia (AML) in complete remission defined by cytomorphological criteria. An important rea...